Dr. Alex Ferenczy is a clinical advisor for LifeSpex, Inc.
Optical imaging of the cervix
Article first published online: 22 OCT 2003
DOI: 10.1002/cncr.11678
Copyright © 2003 American Cancer Society
Issue
1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470)
Cancer
Special Issue: Proceedings of the Second International Conference on Cervical Cancer
Supplement: Second International Conference on Cervical Cancer
Volume 98, Issue Supplement S9, pages 2015–2027, 1 November 2003
Additional Information
How to Cite
Drezek, R. A., Richards-Kortum, R., Brewer, M. A., Feld, M. S., Pitris, C., Ferenczy, A., Faupel, M. L. and Follen, M. (2003), Optical imaging of the cervix. Cancer, 98: 2015–2027. doi: 10.1002/cncr.11678
Publication History
- Issue published online: 22 OCT 2003
- Article first published online: 22 OCT 2003
- Manuscript Accepted: 29 APR 2003
- Manuscript Revised: 25 APR 2003
- Manuscript Received: 31 OCT 2002
- Abstract
- Article
- References
- Cited By
Keywords:
- photonics;
- optical technology;
- detection;
- precancerous lesions;
- uterine cervix
Abstract
Recent advances in fiber optics, sources and detectors, imaging, and computer-controlled instrumentation have stimulated a period of unprecedented growth in the development of photonics technologies for a wide variety of diagnostic and therapeutic clinical applications. These include the application of quantitative optical spectroscopy and imaging for the detection of precancerous lesions in the uterine cervix, a topic of interest at the Second International Conference on Cervical Cancer, which was held April 11–14, 2002. Investigators have applied the Littenberg method of emerging technology assessment to new optical methods used to detect cervical neoplasia. Currently, such technologies as fluorescence spectroscopy (the combination of fluorescence and diffuse reflectance spectroscopy), tri-modal spectroscopy, and light-scattering spectroscopy that probe the spectral characteristics of tissue are being investigated. Optical technologies that create images of subcellular structure without biopsy subsequent to pathology that currently are under investigation include in vivo confocal imaging and optical coherence tomography. Numerous small studies have demonstrated the potential of these optical technologies. What remains to be elucidated are the fundamental biophysical origins of variations in remitted optical signals between normal and dysplastic tissue. Large multicenter randomized controlled trials are needed to confirm the detection and imaging capabilities of optical technology. Furthermore, the development of contrast agents that could boost detection with these technologies is needed, and basic biologic characterization of signals should be pursued. Applying the Littenberg assessment will help ensure that superior, not simply alternative, technologies are implemented. Cancer 2003;98 (9 Suppl):2015–2027. © 2003 American Cancer Society.

1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)